Persistent hypermetabolism and longitudinal energy expenditure in critically ill patients with COVID-19

John Whittle 1, Jeroen Molinger 1, David MacLeod 1, Krista Haines 2, Paul E. Wischmeyer 1,2* for the LEEP-COVID Study Group

COVID-19 infection results in respiratory failure requiring ICU care in a small, yet significant, number of patients [1]. The longitudinal metabolic phenotype and energy expenditure of this novel pandemic disease has yet to be described. As a marked and often prolonged, systemic inflammatory response (SIRS) has been suggested to be a hallmark of severe COVID-19 infection [1], we hypothesized a prolonged hypermetabolic state would evolve over ICU stay that would persist beyond the 7–10 day hypermetabolic phase described previously in other ICU conditions [2].

Further, understanding the energy expenditure of COVID-19 ICU patients is essential to help determine safe, optimal nutrition needs for the ICU provider [3], as both over-/underfeeding is associated with increased ICU mortality [3, 4]. Prediction of resting energy expenditure (pREE) using standardized formulas or bodyweight calculations often correlates poorly with measured REE (mREE) [3]. Thus, our aim was to assess longitudinal mREE via indirect calorimetry (IC) in intubated COVID-19 patients.

Here, we report the first results from the LEEP-COVID study (clinicaltrials.gov NCT04350073) from March to May, 2020. Following IRB approval, IC was conducted every 72 h (Q-NRG, COSMED/BAXTER, USA) [5]. Prior to testing, patients were confirmed to be in stable condition with only steady-state measures for ≥ 20 min considered valid. mREE was compared to pREE, which was calculated at same timepoints via commonly utilized Harris-Benedict equation (HBE). For calculations, actual body weight (ABW) was used for non-obese (BMI < 30) and both actual and adjusted body weight (AdjBW) was utilized for obese subjects (BMI > 30) [3].

Data from 22 COVID-19 ICU patients are summarized in Table 1 and Fig. 1. During the 1st ICU week, mREE was observed to fall between 15 and 20 kcal/kg (for ABW in BMI < 30 and AdjBW in obese subjects [3]). Increasing hypermetabolism and wider variability in mREE were observed post-1st ICU week. Unlike data from smaller studies in other ICU populations [1], observed hypermetabolism persisted, and in fact increased during 3rd ICU week (mean mREE = 150% pREE in 3rd ICU week). Certain individuals exhibited metabolic rates greater than two-times predicted via HBE, which significantly underpredicted REE post-1st ICU week. Changes in
mREE may not be significantly related to severity of organ failure and only minorly affected by paralysis/prone positioning, as these were not significantly different over the study period (Table 1).

Longitudinal IC data presented here demonstrate a progressive hypermetabolic phenotype beginning 1 week post-intubation in COVID-19 ICU patients, with significantly greater mREE versus predictive equations or ASPEN-recommended 11–14 kcal/kg ABW for obese subjects used currently to determine energy requirements. Our data support use of standard predictive equations or ~ 20 kcal/kg as a reasonable approximation of mREE in 1st ICU week in COVID-19 patients. Current ESPEN/ASPEN ICU guidelines suggest hypocaloric (~ 70% pREE) feeding during acute phase to prevent overfeeding risk as it is believed ICU patients have initial early endogenous nutrient production that we currently are unable to measure [3, 4].

To our knowledge, this is the first description of longitudinal mREE in a COVID-19 ICU population. The COVID-19 metabolic phenotype may be unique from previously described ICU models of metabolic response [2], with a more prolonged hypermetabolic phase that may be independent of severity of organ failure and, as previously published, may only be minorly affected by interventions such as paralysis [6]. Further, it is one of the largest single-ICU diagnosis cohorts with longitudinal IC measures for 21 days. In conclusion, we demonstrate progressive hypermetabolism and considerable variation in REE throughout ICU stay. We hope this data assists ICU clinicians in further understanding the effects of COVID-19 on metabolism and in assessing nutrition care needs. These data suggest personalization of nutrition delivery, including IC use [3, 5], should be considered to provide more accurate assessments of energy expenditure and help guide nutrition delivery in COVID-19 ICU patients.

Table 1 Baseline characteristics, clinical care and outcomes, and indirect calorimetry measured resting energy expenditure in COVID-19 ICU patients

(a) Baseline characteristics (n = 22)

| Characteristic                        | Value          |
|---------------------------------------|----------------|
| Age (mean, range)                     | 58 (31–88)     |
| Male sex (n, %)                        | 13 (59)        |
| Race (n, %)                            |                |
| African-American/Black                | 12 (54)        |
| Caucasian/White                       | 7 (32)         |
| Hispanic                              | 3 (14)         |
| BMI (mean, range)                     | 30.7 (17.4–48.1)|
| BMI > 30 (%)                          | 55             |
| Ventilator days (21-day study period only) (mean, sd) | 14.4 (4.7) |
| Mortality (21-day study period only) (n, %) | 3 (14) |
| Mortality (hospital mortality) (n, %)  | 5 (22)         |

(b) Energy expenditure/data

| Day     | Measured REE in absolute kCal/day (all patients) (median, IQR) | p value |
|---------|-----------------------------------------------------------------|---------|
| D0–7    | 1568 (1175–2215)                                                |         |
| D7–14   | 1830 (1465–2467)                                                |         |
| D14–21  | 2789 (1776–3262)                                                | < 0.05  |

(c) Clinical data

| Day     | Use of prone positioning (%) (mean, sd) | p value |
|---------|-----------------------------------------|---------|
| D0–7    | 12.3 (8.6)                              |         |
| D7–14   | 7 (2.4)                                 |         |
| D14–21  | 12.2 (4.3)                              | 0.17    |

Notes: All obese subjects had BMI measures between 30 and 50. p values are for Kruskal-Wallis test
Subjects were withdrawn from this analysis upon extubation or death

BW body weight; BMI body mass index; REE resting energy expenditure; predicted REE via Harris-Benedict equation; AdjBW adjusted bodyweight, ABW actual body weight, obesity BMI > 30, non-obese BMI < 30, IQR interquartile range, SOFA Sequential Organ Failure Assessment, sd standard deviation
Acknowledgements

The primary authors acknowledge the commitment and many hundreds of hours spent conducting this trial by the study research coordinators, respiratory therapists, dietitians, critical care attendings, nurses, and other ICU staff at Duke University Hospital that made the many daily measurements in critically ill COVID-19 patients possible.

We also acknowledge the LEEP-COVID study group co-authors who made this research possible: Anthony Sung MD, Marat Fudim MD, Lindsie Boerger RD, Kathryn Lessig RD, Jessica Lumbard BS, Leslie C. Murray RD, Sue Steves RD, Jhana Parikh BS, Jacob Ribet BS, RRT LDN, and Melanie Hollidge MD.

Authors’ contributions

Concept and design: Whittle, Molinger, and Wischmeyer
Acquisition, analysis, or interpretation of data: Whittle, Molinger, MacLeod, Parikh, Ribet, Wischmeyer, Sung, Boerger, Murray, Steves, Lessig, Lumbard, Fudim, and Hollidge
Drafting of the manuscript: Whittle, Haines, and Wischmeyer
Critical revision of the manuscript for important intellectual content: Whittle, MacLeod, Haines, Wischmeyer, and Sung
Statistical analysis: Whittle
Administrative, technical, or material support: Molinger, Parikh, Ribet, Boerger, Murray, Steves, Lumbard, Fudim, and Hollidge
Supervision: Whittle and Wischmeyer
The authors read and approved the final manuscript.

Funding

This study was funded in part by an investigator-initiated grant from Baxter Inc. (Deerfield, IL) to Paul E. Wischmeyer via Duke University. The sponsor (Baxter) did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Only the authors and investigators at Duke University participated in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials

All raw data available upon request.
Ethics approval and consent to participate
LEEP-COVID study was approved by Duke Institutional Review Board. A
waiver of consent was granted by Duke IRB due to minimal risk to patient
from FDA-approved QNRG indirect calorimeter assessment. All patients were
provided an information sheet when able to be awake and oriented (if pos-
sible) and given option to withdraw from the study with no data retained.

Consent for publication
Not applicable; all authors have seen and approved the final version of the
manuscript.

Competing interests
Dr. Wischmeyer reports receiving investigator-initiated grant funding related
to this work from National Institutes of Health, Canadian Institutes of Health
Research, Baxter, and Fresenius. Dr. Wischmeyer has served as a consultant
to Abbott, Fresenius, Baxter, Cardinal Health, and Nutricia, for research related
to this work. Dr. Wischmeyer has received unrestricted gift donation for nutri-
tion research from Musclesound. Dr. Wischmeyer has received honoraria or
travel expenses for CME lectures on improving nutrition care from Abbott,
Baxter, and Danone-Nutricia.

Received: 3 July 2020 Accepted: 14 September 2020
Published online: 28 September 2020

References
1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19 [published online ahead
of print, 2020 May 15]. N Engl J Med. 2020; https://doi.org/10.1056/
NEJMc2009575.
2. Uehara M, Plank LD, Hill GL. Components of energy expenditure in patients
with severe sepsis and major trauma: a basis for clinical care. Crit Care Med.
1999;27(7):1295–302.
3. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP,
Hiesmayr M, Mayer K, Montejo JC, Pichard C, et al. ESPEN guideline on
clinical nutrition in the intensive care unit. Clin Nutr. 2019;38(1):48–79.
4. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR,
Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, et al.
Guidelines for the provision and assessment of nutrition support therapy in
the adult critically ill patient: Society of Critical Care Medicine (SCCM) and
American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J
Parenter Enteral Nutr. 2016;40(2):159–211.
5. Oshima T, Delsoglio M, Dupertuis YM, Singer P, De Waele E, Veraar C,
Heidegger CP, Wernermann J, Wischmeyer PE, Berger MM et al: The clinical
evaluation of the new indirect calorimeter developed by the ICAIC project.
Clin Nutr. 2020;6261-5614(20)30040-6. DOI: https://doi.org/10.1016/j.clinu.
2020.01.017. Online ahead of print.
6. Koekkoek WAC, Menger YA, van Zanten FJL, van Dijk D, van Zanten ARH.
The effect of cisatracurium infusion on the energy expenditure of critically
ill patients: an observational cohort study. Crit Care. 2020;24(1):32.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions